Effects of Intravitreous Aflibercept Injection in Pachychoroid Neovasculopathy: Comparison with Typical Neovascular Age-Related Macular Degeneration

References

• Klein ML, Ferris FL, Armstrong J, et al. Retinal precursors and the development of geographic atrophy in age-related macular degeneration. Ophthalmology. 2008;115(6):1026–1031. doi:10.1016/j.ophtha.2007.08.030
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–1444. doi:10.1056/NEJMoa062655
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi:10.1056/NEJMoa054481
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–2548. doi:10.1016/j.ophtha.2012.09.006
   PubMed Web of Science ®Google Scholar
• Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR Study. Ophthalmology. 2009;116(1):57–65.e5. doi:10.1016/j.ophtha.2008.10.018
   PubMed Web of Science ®Google Scholar
• Fung AT, Yannuzzi LA, Freund K. Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration. Retina. 2012;32(9):1829–1837. doi:10.1097/IAE.0b013e3182680a66
   PubMed Web of Science ®Google Scholar
• Warrow DJ, Hoang QV, Freund KB. Pachychoroid pigment epitheliopathy. Retina. 2013;33(8):1659–1672. doi:10.1097/IAE.0b013e3182953df4
   PubMed Web of Science ®Google Scholar
• Pang CE, Freund KB. Pachychoroid neovasculopathy. Retina. 2015;35(1):1–9. doi:10.1097/IAE.0000000000000331
   PubMed Web of Science ®Google Scholar
• Miyake M, Ooto S, Yamashiro K, et al. Pachychoroid neovasculopathy and age-related macular degeneration. Sci Rep. 2015;5(1):16204. doi:10.1038/srep16204
   PubMed Web of Science ®Google Scholar
• Tagawa M, Ooto S, Yamashiro K, et al. Characteristics of pachychoroid neovasculopathy. Sci Rep. 2020;10(1):16248. doi:10.1038/s41598-020-73303-w
   PubMed Web of Science ®Google Scholar
• Dansingani KK, Balaratnasingam C, Naysan J, Freund KB. En face imaging of pachychoroid spectrum disorders with swept-source optical coherence tomography. Retina. 2016;36(3):499–516. doi:10.1097/IAE.0000000000000742
   PubMed Web of Science ®Google Scholar
• Balaratnasingam C, Lee W-K, Koizumi H, et al. Polypoidal choroidal vasculopathy. Retina. 2016;36(1):1–8. doi:10.1097/IAE.0000000000000774
   PubMed Web of Science ®Google Scholar
• Lehmann M, Bousquet E, Beydoun T, Behar-Cohen F. Pachychoroid. Retina. 2015;35(1):10–16. doi:10.1097/IAE.0000000000000287
   PubMed Web of Science ®Google Scholar
• Gallego-Pinazo R, Dolz-Marco R, Gómez-Ulla F, et al. Pachychoroid diseases of the macula. Med Hypothesis Discov Innov Ophthalmol. 2014;3:111–115.
   PubMedGoogle Scholar
• Imamura Y, Fujiwara T, Margolis R, Spaide RF. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina. 2009;29(10):1469–1473. doi:10.1097/IAE.0b013e3181be0a83
   PubMed Web of Science ®Google Scholar
• Padrón-Pérez N, Arias L, Rubio M, et al. Changes in choroidal thickness after intravitreal injection of anti-vascular endothelial growth factor in pachychoroid neovasculopathy. Invest Ophthalmol Vis Sci. 2018;59(2):1119–1124. doi:10.1167/iovs.17-22144
   PubMed Web of Science ®Google Scholar
• Matsumoto H, Hiroe T, Morimoto M, et al. Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and type 1 neovascular age-related macular degeneration. Jpn J Ophthalmol. 2018;62(2):144–150. doi:10.1007/s10384-018-0562-0
   PubMed Web of Science ®Google Scholar
• Hata M, Yamashiro K, Ooto S, et al. Intraocular vascular endothelial growth factor levels in pachychoroid neovasculopathy and neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2017;58(1):292–298. doi:10.1167/iovs.16-20967
   PubMed Web of Science ®Google Scholar
• Takahashi A, Ooto S, Yamashiro K, et al. Pachychoroid geographic atrophy: clinical and genetic characteristics. Ophthalmol Retina. 2018;2(4):295–305. doi:10.1016/j.oret.2017.08.016
   PubMedGoogle Scholar
• Pang CE, Shah VP, Sarraf D, Freund KB. Ultra-widefield imaging with autofluorescence and indocyanine green angiography in central serous chorioretinopathy. Am J Ophthalmol. 2014;158(2):362–371.e2. doi:10.1016/j.ajo.2014.04.021
   PubMed Web of Science ®Google Scholar
• Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the Age-Related Eye Disease Study report number 6. Am J Ophthalmol. 2001;132(5):668–681. doi:10.1016/S0002-9394(01)01218-1
   PubMed Web of Science ®Google Scholar
• Spaide RF, Koizumi H, Pozonni MC. Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol. 2008;146(4):496–500. doi:10.1016/j.ajo.2008.05.032
   PubMed Web of Science ®Google Scholar
• Yannuzzi LA. Type A behavior and central serous chorioretinopathy. Trans Am Ophthalmol Soc. 1986;84:799–845.
   PubMedGoogle Scholar
• Tittl MK, Spaide RF, Wong D, et al. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol. 1999;128(1):63–68. doi:10.1016/S0002-9394(99)00075-6
   PubMed Web of Science ®Google Scholar
• Haimovici R, Koh S, Gagnon DR, et al. Risk factors for central serous chorioretinopathy: a Case–Control Study. Ophthalmology. 2004;111(2):244–249. doi:10.1016/j.ophtha.2003.09.024
   PubMed Web of Science ®Google Scholar
• Oishi A, Tsujikawa A, Yamashiro K, et al. One-year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcome. Am J Ophthalmol. 2015;159(5):853–860.e1. doi:10.1016/j.ajo.2015.01.018
   PubMed Web of Science ®Google Scholar
• Koizumi H, Kano M, Yamamoto A, et al. Subfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration. Ophthalmology. 2016;123(3):617–624. doi:10.1016/j.ophtha.2015.10.039
   Web of Science ®Google Scholar
• Coscas F, Coscas G, Lupidi M, et al. Restoration of outer retinal layers after aflibercept therapy in exudative AMD: prognostic value. Invest Ophthalmol Vis Sci. 2015;56(6):4129–4134. doi:10.1167/iovs.15-16735
   Web of Science ®Google Scholar
• Eleftheriadou M, Vazquez-Alfageme C, Citu CM, et al. Long-term outcomes of aflibercept treatment for neovascular age-related macular degeneration in a clinical setting. Am J Ophthalmol. 2017;174:160–168. doi:10.1016/j.ajo.2016.09.038
   PubMed Web of Science ®Google Scholar
• Hata M, Oishi A, Tsujikawa A, et al. Efficacy of intravitreal injection of aflibercept in neovascular age-related macular degeneration with or without choroidal vascular hyperpermeability. Invest Ophthalmol Vis Sci. 2014;55(12):7874–7880. doi:10.1167/iovs.14-14610
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Kaiser PK, Korobelnik J-F, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration. Ophthalmology. 2014;121(1):193–201. doi:10.1016/j.ophtha.2013.08.011
   PubMed Web of Science ®Google Scholar
• Koizumi H, Kano M, Yamamoto A, et al. Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration. Am J Ophthalmol. 2015;159(4):627–633.e1. doi:10.1016/j.ajo.2014.12.025
   Web of Science ®Google Scholar
• Mazaraki K, Fassnacht-Riederle H, Blum R, et al. Change in choroidal thickness after intravitreal aflibercept in pretreated and treatment-naive eyes for neovascular age-related macular degeneration. Br J Ophthalmol. 2015;99(10):1341–1344. doi:10.1136/bjophthalmol-2015-306636
   Web of Science ®Google Scholar
• Margolis R, Spaide RF. A Pilot Study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. Am J Ophthalmol. 2009;147(5):811–815. doi:10.1016/j.ajo.2008.12.008
   PubMed Web of Science ®Google Scholar
• Wb W, Xu L, Jonas JB, et al. Subfoveal choroidal thickness: the Beijing Eye Study. Ophthalmology. 2013;120(1):175–180. doi:10.1016/j.ophtha.2012.07.048
   Web of Science ®Google Scholar
• Lowe J, Araujo J, Yang J, et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res. 2007;85(4):425–430. doi:10.1016/j.exer.2007.05.008
   PubMed Web of Science ®Google Scholar
• Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti–vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26(8):859–870. doi:10.1097/01.iae.0000242842.14624.e7
   PubMed Web of Science ®Google Scholar
• Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol. 1998;274(3):H1054–8. doi:10.1152/ajpheart.1998.274.3.H1054
   PubMedGoogle Scholar
• Sayanagi K, Sharma S, Kaiser PK. Photoreceptor status after antivascular endothelial growth factor therapy in exudative age-related macular degeneration. Br J Ophthalmol. 2009;93(5):622–626. doi:10.1136/bjo.2008.151977
   Web of Science ®Google Scholar
• Shin HJ, Chung H, Kim HC. Association between foveal microstructure and visual outcome in age-related macular degeneration. Retina. 2011;31(8):1627–1636. doi:10.1097/IAE.0b013e31820d3d01
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Waldstein SM. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res. 2016;50:1–24. doi:10.1016/j.preteyeres.2015.07.007
   PubMed Web of Science ®Google Scholar
• Mathew R, Richardson M, Sivaprasad S. Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with neovascular age-related macular degeneration treated with ranibizumab. Am J Ophthalmol. 2013;155(4):720–726.e1. doi:10.1016/j.ajo.2012.11.003
   Web of Science ®Google Scholar